Evidence map›Paper›PMID 20515737›Full record

ReviewFrontiers in bioscience (Landmark edition)2010

Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity.

Jietang Mai, Hong Wang, Xiao-Feng Yang

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Frontiers in bioscience (Landmark edition), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01678222 (The Role of Functionally Relevant Cyclooxygenase-2), which is not on this map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01678222 completednot on this mapstarted 2013, after this paper: background citation

The Role of Functionally Relevant Cyclooxygenase-2 (COX-2) Gene Single Nucleotide Polymorphisms - 765G>C and 8473T>C in Lymphocyte Differentiation

TypeobservationalSponsorNational Institute of Environmental Health Sciences (NIEHS)Ran2013Enrolled117ConditionsAllergic Inflammation, Asthma
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. International journal of molecular sciences · 2023
    Article
  6. 29 mJournal of immunology research · 2022
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Autoimmunity as the comet tail of COVID-19 pandemic.World journal of clinical cases · 2020
    Review
  14. Article
  15. Immunomodulators in Lymphoma.Current treatment options in oncology · 2020
    Review
  16. Article
  17. Celastrol suppresses experimental autoimmune encephalomyelitis via MAPK/SGK1-regulated mediators of autoimmune pathology.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019
    Article
  18. The Immune Escape Mechanisms ofInternational journal of molecular sciences · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jietang MaiDepartment of Pharmacology and Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Hong Wang
Xiao-Feng Yang
Temple University · US

Funding

Atherogenic mechanisms with homocysteineR01HL077288 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2004 to 2014
$3.8M
Inhibition of Endothelial Growth by HomocysteineR01HL067033 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2002 to 2011
$3.0M
Roles of Interleukin-17 in Endothelial CellsR01HL108910 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2011 to 2015
$1.9M
Suppression of vascular endothelial cell inflammationR01HL094451 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2009 to 2013
$1.8M
Role of HHcy in diabetic vascular diseaseR01HL082774 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2006 to 2010
$1.8M
NHLBI NIH HHS HL094451NHLBI NIH HHS HL67033NHLBI NIH HHS HL77288NHLBI NIH HHS HL82774NHLBI NIH HHS R01 HL067033NHLBI NIH HHS R01 HL077288NHLBI NIH HHS R01 HL082774NHLBI NIH HHS R01 HL094451NHLBI NIH HHS R01 HL108910
6 · The paper itself

Abstract

T helper 17 cells (Th17) are a new CD4+ T helper subset that has been implicated in inflammatory and autoimmune diseases. Th17, along with CD4(+)CD25(high) Foxp3(+) regulatory T cells (Tregs) and other new T helper subsets, have expanded the Th1-Th2 paradigm. Although this new eight-subset paradigm significantly improved our understanding on the differentiation and regulation of CD4+ T helper subsets, many questions remain to be answered. Here we will briefly review the following issues: a) Old Th1-Th2 paradigm versus new multi-subset paradigm; b) Structural features of IL-17 family cytokines; c) Th17 cells; d) Effects of IL-17 on various cell types and tissues; e) IL-17 receptor and signaling pathways; f) Th17-mediated inflammations; and g) Protective mechanisms of IL-17 in infections. Lastly, we will examine the interactions of Th17 and Treg in autoimmune diseases and inflammation: Th17 cells interplay with Tregs. Regulation of autoimmunity and inflammation lies in the interplays of the different T helper subsets, therefore, better understanding of these subsets' interactions would greatly improve our approaches in developing therapy to combat inflammatory and autoimmune diseases.

Indexed as

AnimalsAutoimmune DiseasesAutoimmunityCytokinesForkhead Transcription FactorsHumansInflammationInterleukin-17T-Lymphocytes, Helper-InducerT-Lymphocytes, RegulatoryCytokinesForkhead Transcription FactorsFOXP3 protein, humanInterleukin-17

Identifiers

PMID20515737
PMCPMC2880832
OpenAlexW2022920759

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.